Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager
-
WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and...
-
Wilmington, Delaware, United States, Transparency Market Research, Inc. , Sept. 09, 2024 (GLOBE NEWSWIRE) -- The global companion diagnostic tests in oncology market (الاختبارات التشخيصية المصاحبة...
-
Beamion LUNG-1, Phase Ib met its primary endpoint, demonstrating a meaningful objective response rate (ORR) of 66.7%, as assessed by blinded independent central review (BICR)1Preliminary activity in...
-
Austin, TX, USA, May 20, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Colorectal Cancer Market Size, Trends and Insights By Type of Treatment (Surgery,...
-
Austin, TX, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Breast Cancer Therapeutics Market Size, Trends and Insights By Type of Therapy...
-
NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
-
21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for trial; enrollment proceeding to Part 2 of Cohort A78% of patients had tumor...
-
ROCKVILLE, MD, Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
-
Primary endpoint of Phase 3 study met with MARGENZA (margetuximab-cmkb) showing a 24% Progression Free Survival (PFS) relative risk reduction compared to Herceptin® (trastuzumab), both with...